CytomX Therapeutics (CTMX) Net Equity Issued and Repurchased (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Net Equity Issued and Repurchased came in at $228.4 million in Q1 2026, up 1300.93% on a QoQ basis from $16.3 million in Q4 2025.
CytomX Therapeutics (CTMX) Net Equity Issued and Repurchased (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 7 years of Net Equity Issued and Repurchased data on file, last reported at $228.4 million in Q1 2026.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $228.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $338.0 million (up 15927.69% YoY) and the FY2025 annual result came in at $109.6 million, up 1486.84% from the prior year.
- Net Equity Issued and Repurchased improved to $228.4 million in Q1 2026, from $16.3 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $228.4 million in Q1 2026 to a low of $43000.0 in Q2 2024.
- A 3-year average of $68.0 million and a median of $16.3 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
- The widest YoY moves for Net Equity Issued and Repurchased: up 217046.51% in 2025, down 688.96% in 2025.
- Tracing CTMX's Net Equity Issued and Repurchased over 3 years: stood at $2.1 million in 2024, then surged by 688.96% to $16.3 million in 2025, then soared by 1300.93% to $228.4 million in 2026.
- The last three Net Equity Issued and Repurchased figures came in at $228.4 million (Q1 2026), $16.3 million (Q4 2025), and $93.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 56,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56,000.00 |
| Jun 30, 2026 | 56,000.00 |
| Mar 31, 2026 | 228.35 Mn |
| Mar 31, 2026 | 228.35 Mn |
| Dec 31, 2025 | 16.30 Mn |
| Dec 31, 2025 | 16.30 Mn |
| Jun 30, 2025 | 93.37 Mn |
| Jun 30, 2025 | 93.37 Mn |
| Dec 31, 2024 | 2.07 Mn |
| Dec 31, 2024 | 2.07 Mn |
| Jun 30, 2024 | 43,000.00 |
| Jun 30, 2024 | 43,000.00 |
| Mar 31, 2021 | 107.71 Mn |
| Mar 31, 2021 | 107.71 Mn |
| Dec 31, 2020 | 11.30 Mn |
| Dec 31, 2020 | 11.30 Mn |
| Sep 30, 2015 | 39,000.00 |
| Sep 30, 2015 | 39,000.00 |
| Jun 30, 2015 | 73.20 Mn |
| Jun 30, 2015 | 73.20 Mn |